General Information of Drug (ID: DM8P9ST)

Drug Name
PF-4800567 Drug Info
Synonyms PF4800567; PF 4800567
Indication
Disease Entry ICD 11 Status REF
Chronic lymphocytic leukaemia 2A82.0 Preclinical [1]
Cross-matching ID
PubChem CID
53472153
ChEBI ID
CHEBI:87237
CAS Number
CAS 1188296-52-7
TTD Drug ID
DM8P9ST

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Preclinical Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
IC261 DMXB95R Pancreatic cancer 2C10 Preclinical [3]
D-4476 DMHD3R8 Chronic lymphocytic leukaemia 2A82.0 Preclinical [4]
PF-670462 DMTJBP9 Chronic lymphocytic leukaemia 2A82.0 Preclinical [5]
PMID24900428C14 DMU4BL2 Discovery agent N.A. Investigative [6]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Umbralisib DMYRBO1 Follicular lymphoma 2A80 Approved [7]
IC261 DMXB95R Pancreatic cancer 2C10 Preclinical [3]
PF-670462 DMTJBP9 Chronic lymphocytic leukaemia 2A82.0 Preclinical [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Casein kinase I delta (CSNK1D) TTH30UI KC1D_HUMAN Inhibitor [2]
Casein kinase I epsilon (CSNK1E) TTA8PLI KC1E_HUMAN Inhibitor [2]

References

1 Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
2 Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period. J Pharmacol Exp Ther. 2009 Aug;330(2):430-9.
3 Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem. 2000 Jun 30;275(26):20052-60.
4 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
5 Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood. 2018 Mar 15;131(11):1206-1218.
6 Structure-Based Design of Potent and Selective CK1gamma Inhibitors. ACS Med Chem Lett. 2012 Oct 18;3(12):1059-64.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021